Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 196 entries
View as:

A Community-based Intervention Among Active Drug Users in Montpellier

Phase: N/A Priority: Normal
NCT ID: NCT04008927 Org: User:
Start: 09/18/20 End: 09/10/21 Due: 09/10/22

National Survey About Trajectory and Life Conditions of HIV Trans People in France

Phase: N/A Priority: Normal
NCT ID: NCT04849767 Org: User:
Start: 10/01/20 End: 12/31/23 Due: 12/31/24

DRug Use & Infections in ViEtnam: TuBerculosis Control

Phase: N/A Priority: Normal
NCT ID: NCT05655702 Org: User:
Start: 10/02/23 End: 11/30/25 Due: 11/30/26

Drug Use & Infections in ViEtnam: Mental Health Intervention for INjecting Drug Users

Phase: N/A Priority: Normal
NCT ID: NCT05886504 Org: User:
Start: 03/28/22 End: 07/28/24 Due: 07/28/25

A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults

Phase: N/A Priority: Normal
NCT ID: NCT04844775 Org: User:
Start: 08/05/22 End: 09/30/24 Due: 09/30/25

Tenofovir As Prevention Of Hepatitis b Mother-to-child Transmission

Phase: N/A Priority: Normal
NCT ID: NCT02937779 Org: User:
Start: 10/04/17 End: 03/31/20 Due: 03/31/21

Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread?

Phase: N/A Priority: Normal
NCT ID: NCT01895920 Org: User:
Start: 01/31/13 End: 02/28/18 Due: 02/28/19

Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies with Early Access Authorization in Immunocompromised Patients. a Prospective Cohort.

Phase: N/A Priority: Normal
NCT ID: NCT05216588 Org: User:
Start: 01/26/22 End: 10/31/24 Due: 10/31/25

A Cross Sectional Evaluation of the Development in Children Age 4 to 7 Infected or Exposed to HIV From the ANRS 12140 Cohort (Pediacam)

Phase: N/A Priority: Normal
NCT ID: NCT02570334 Org: User:
Start: 12/31/15 End: 12/31/16 Due: 12/31/17

ANRS12373 GUNDO SO - Evaluation of an Empowerment Program for WLHIV in Mali

Phase: N/A Priority: Normal
NCT ID: NCT03795415 Org: User:
Start: 05/27/19 End: 05/31/21 Due: 05/31/22

Disability and HIV: Vulnerability of People With Disabilities to HIV Infection in Sub-Saharan Africa

Phase: N/A Priority: Normal
NCT ID: NCT02192658 Org: User:
Start: 11/30/14 End: 07/31/16 Due: 07/31/17

Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV

Phase: N/A Priority: Normal
NCT ID: NCT03324633 Org: User:
Start: 06/30/05 End: 12/31/22 Due: 12/31/23

Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients

Phase: N/A Priority: Normal
NCT ID: NCT02384967 Org: User:
Start: 03/31/15 End: 10/31/16 Due: 10/31/17

ANRS CO24 OncoVIHAC (Onco VIH Anti Checkpoint)

Phase: N/A Priority: Normal
NCT ID: NCT03354936 Org: User:
Start: 01/17/18 End: 06/15/22 Due: 06/15/23

Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control

Phase: N/A Priority: Normal
NCT ID: NCT05300035 Org: User:
Start: 04/11/24 End: 12/10/28 Due: 12/10/29

Seroprevalence of Monkeypox Infection Among People Living With HIV and PrEP Users

Phase: N/A Priority: Normal
NCT ID: NCT05922735 Org: User:
Start: 09/01/23 End: 02/01/25 Due: 02/01/26

A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)

Phase: N/A Priority: Normal
NCT ID: NCT02527096 Org: User:
Start: 09/17/15 End: 03/31/17 Due: 03/31/18

X-linked Biological Response to HIV Sensing: the ANRS EP 53 Study

Phase: N/A Priority: Normal
NCT ID: NCT01952587 Org: User:
Start: 11/30/13 End: 06/30/15 Due: 06/30/16

Partner Notification of Sexually Transmitted Infections (STIs) in Testing Centers

Phase: N/A Priority: Normal
NCT ID: NCT04921618 Org: User:
Start: 07/12/21 End: 12/31/22 Due: 12/31/23

Role of the IL33/Amphiregulin Pathway as a Potential Therapeutic Target in HIV Infection

Phase: N/A Priority: Normal
NCT ID: NCT03622177 Org: User:
Start: 09/30/18 End: 09/30/23 Due: 09/30/24

Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin

Phase: N/A Priority: Normal
NCT ID: NCT01335529 Org: User:
Start: 05/31/11 End: 05/31/14 Due: 05/31/15

Prevalence and Longitudinal Follow-up of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo.

Phase: N/A Priority: Normal
NCT ID: NCT04910438 Org: User:
Start: 06/24/21 End: 12/31/24 Due: 12/31/25

Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3

Phase: N/A Priority: Normal
NCT ID: NCT02057796 Org: User:
Start: 09/30/14 End: 04/30/18 Due: 04/30/19

Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04842682 Org: User:
Start: 03/29/21 End: 11/29/24 Due: 11/29/25

Post-COVID-19 Condition: Observational Study in Vietnam

Phase: N/A Priority: Normal
NCT ID: NCT06022211 Org: User:
Start: 12/31/23 End: 12/31/24 Due: 12/31/25